NKGen Biotech, Inc. Common Stock
NKGen Biotech, Inc., a clinical-stage biotechnology company, develops and commercializes cell therapies for neurodegenerative and oncological diseases based on activated natural killer (NK) cells in the United States. The company develops SNK01, an autologous NK cell therapy candidate in Phase I/IIa trial for the treatment of neurodegenerative diseases, such as Alzheimer's and Parkinson's disease… Read more
Market Cap & Net Worth: NKGen Biotech, Inc. Common Stock (NKGN)
NKGen Biotech, Inc. Common Stock (PINK:NKGN) has a market capitalization of $20.37 Million ($20.37 Million) as of March 19, 2026. Listed on the PINK stock exchange, this USA-based company holds position #29605 globally and #9801 in its home market, demonstrating a -8.77% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying NKGen Biotech, Inc. Common Stock's stock price $0.16 by its total outstanding shares 130602230 (130.60 Million).
NKGen Biotech, Inc. Common Stock Market Cap History: 2025 to 2025
NKGen Biotech, Inc. Common Stock's market capitalization history from 2025 to 2025. Data shows growth from $20.37 Million to $20.37 Million (0.00% CAGR).
NKGen Biotech, Inc. Common Stock Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how NKGen Biotech, Inc. Common Stock's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of NKGN by Market Capitalization
Companies near NKGen Biotech, Inc. Common Stock in the global market cap rankings as of March 19, 2026.
Key companies related to NKGen Biotech, Inc. Common Stock by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #162 globally with a market cap of $117.09 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #281 globally with a market cap of $74.80 Billion USD.
- CSL Limited (PINK:CMXHF): Ranked #344 globally with a market cap of $63.46 Billion USD.
- argenx SE (OTCGREY:ARGNF): Ranked #500 globally with a market cap of $42.99 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #162 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $117.09 Billion | $462.49 |
| #281 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $74.80 Billion | $759.05 |
| #344 | CSL Limited | PINK:CMXHF | $63.46 Billion | $149.87 |
| #500 | argenx SE | OTCGREY:ARGNF | $42.99 Billion | $697.42 |
NKGen Biotech, Inc. Common Stock Historical Marketcap From 2025 to 2025
Between 2025 and today, NKGen Biotech, Inc. Common Stock's market cap moved from $20.37 Million to $ 20.37 Million, with a yearly change of 0.00%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2025 | $20.37 Million | -- |
End of Day Market Cap According to Different Sources
On Mar 18th, 2026 the market cap of NKGen Biotech, Inc. Common Stock was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $20.37 Million USD |
| MoneyControl | $20.37 Million USD |
| MarketWatch | $20.37 Million USD |
| marketcap.company | $20.37 Million USD |
| Reuters | $20.37 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.